US Oncology Reports Fourth Quarter and Fiscal Year 20...(RECONCILIATION OF NET INCOME (LOSS) TO E...)

(in thousands)

(unaudited)

Three Months Three Months

Ended Ended Year Ended

December 31, September 30, December 31,

2007 2006 2007 2007 2006

Net income (loss) $(14,830) $3,253 $(4,194) $(34,973) $26,158

Add back:

Interest expense,

net 36,913 29,547 34,414 137,496 117,088

Income tax

(benefit)

provision (7,869) 3,654 (4,760) (17,447) 18,926

Depreciation and

amortization 23,456 21,660 23,239 89,331 83,334

Amortization of

stock compensation 277 746 15 753 2,149

Minority interest

expense 1,743 660 539 3,619 2,388

Other expense 11,573 - 312 11,885 -

EBITDA 51,263 59,520 49,565 190,664 250,043

Plus:

Loss on

extinguishment

of debt - - - 12,917 -

Impairment and

restructuring

charges 6,771 - 960 15,126 -

Adjusted EBITDA 58,034(1) 59,520(1) 50,525(1) 218,707(1) 250,043(1)

Changes in assets

and liabilities 45,954 29,394 (14,787) 77,708 (97,934)

Deferred income

tax provision

(benefit) (699) 1,414 (10,017) (11,689) 4,422

Interest

expense, net (36,913) (29,547) (34,414) (137,496) (117,088)

Income tax

benefit

(provision) 7,869 (3,654) 4,760 17,447
'/>"/>